Experiences accessing and receiving tumour genetic profiling in Victoria: a consumer-led cross-sectional survey study Authors: Victorian Comprehensive Cancer Centre (VCCC) Alliance Personalised Cancer Care Consumer Reference Group, Victorian Comprehensive Cancer Centre (VCCC) Alliance staff, Research Support Team (University of Melbourne) Published: 2026 ABSTRACT AbstractBackgroundTumour genetic profiling has the potential to significantly improve cancer care by informing targeted treatments and improving patient outcomes. As use increases worldwide, greater attention should be paid to consumer experiences, need and priorities. This study is consumer-led and aims to inform an equitable and ethical roll out of future services by exploring consumer: 1) awareness of tumour genetic profiling, 2) experiences with tumour genetic profiling, and 3) priorities for improving access to and delivery of tumour genetic profiling within Victoria, Australia.MethodsA consumer reference group was formed and supported by experienced researchers and professional staff of a comprehensive cancer centre alliance to develop and conduct the research study. A cross-sectional survey was conducted between January and May 2024, capturing demographic and disease characteristics, along with questions relating to each aim. Both quantitative and qualitative data were collected. Eligible participants were patients diagnosed with cancer whose treatment teams were based in Victoria, Australia, or caregivers of such patients.ResultsOf the 181 respondents (n = 36 carers, n = 145 patients), 23% (n = 44) reported that they (or the person they cared for) had undergone tumour genetic profiling. The majority reported a positive impact, including increased knowledge/understanding (n = 30, 68%) and personalised treatment options (n = 23, 52%), with very low decisional regret (mean: 3/100). However, 14% reported no understanding of the results at all, and confusion was reported as a drawback of testing.Higher education and greater shared decision making were associated with better understanding of results (p = 0.02 and p = 0.04, respectively) and higher education was also associated with greater awareness of genetic tumour profiling (p = 0.008). The primary barriers to uptake were lack of awareness (n = 88, 83%) and lack of perceived benefit from the treatment team (n = 19, 18%). Key strategies for improvement identified by participants included government-subsidised testing and improved patient and clinician education.ConclusionsThis study highlighted gaps in consumer awareness and access to tumour genetic profiling, as well as the benefits of shared decision making. Overall, consumer-led insights emphasise the need for equitable funding, education, and systemic improvements. These findings can inform policies and practices aimed at delivering person-centred cancer care in Victoria and beyond. Future longitudinal research is needed to comprehensively explore these associations and track progress.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16052-9.Keywords: Consumer-led, Patient and public involvement, Tumour genetic profiling, Somatic testing, Molecular testing, Precision oncology, Personalised care, Cancer, Shared decision making, Psycho-oncology Background Tumour genetic profiling (often called somatic testing or molecular testing) is increasingly used worldwide to target cancer treatments and is associated with improved patient outcomes, including survival [1]. For example, in non-small cell lung cancer, identification of EGRF-positive mutations enables the use of targeted therapies (e.g., erlotinib) as a first-line treatment, which has demonstrably improved survival in this cohort compared to chemotherapy [2]. While not all profiling leads to survival benefits, its capacity to predict cancer recurrence risk, tailor treatment strategies, and enhance understanding of tumour biology underscores its growing impact in cancer care [3]. The major challenge for governments and healthcare providers is to fund and then harness these technologies for the benefit of all consumers (patients and caregivers affected by cancer), rather than sub-sectors of the population [4], and to do so in a person-centred and ethical way. In Australia, tumour genetic profiling is publicly funded through the national Medicare Benefits Schedule (MBS), which applies uniformly across all states and territories, including Victoria. Coverage is currently limited to a defined set of genomic tests in specific cancers and clinical contexts. Outside these indications, patients may self-fund, enrol in research programs supported by government, industry, or philanthropy, or, less commonly, access private insurance coverage, which is also regulated at the national level. Coverage decisions are shaped by cancer type, clinical utility, cost-effectiveness, regulatory approval, and inclusion on the MBS, all of which strongly influence equity of access and uptake [5]. At present, there is no national consensus supporting comprehensive genetic profiling across all tumour types. Instead, biomarker testing is recommended only in selected cancers where results inform therapy selection, such as BRCA1/2 and other homologous recombination repair genes in ovarian, prostate, and breast cancers. Broader access to tumour genetic profiling has been facilitated through national initiatives such as Omico’s Cancer Screening Program (CaSP/PrOSPeCT), which offers comprehensive tumour genetic profiling to patients with advanced, rare, or poor-prognosis cancers and often links results to clinical trial opportunities. A summary of tumour genetic profiling reimbursement, access pathways and illustrative examples of MBS-funded testing relevant to Victoria is provided in supplementary file 1. Several studies have provided policy makers and practitioners with important insights into patient needs and experiences in this setting. A systematic review of barriers to genomic testing in oncology (including tumour genetic profiling) [5], suggests that common barriers may include costs, perceived clinical utility (or lack thereof), privacy and confidentiality concerns, and fear of psychological harm. However, the majority of included studies (n = 15, 88%) used hypothetical scenarios, which limits the ability of policy-makers to draw from lived experience in decision-making [6]. One study focused on real-world patient experiences and raised concerns about equitable and empowered access to testing [7]. Namely, of 132 early-stage breast cancer patients treated within a university clinic who were eligible for the Oncotype DX genomic test, only half received it [7]. The most common reason for not undergoing testing was not being offered it by the physician. Undergoing testing was associated with demographic (younger age) and disease characteristics (lower recurrence risk), as well as the patient reporting a more active decision-making style. These results reflect the broader oncology literature on shared decision-making [8], suggesting that outcomes can be improved when physicians inform patients of treatment choices and actively engage them in the decision-making process. However, shared decision-making is not always implemented within practice. Given this study was over a decade ago and focused on early-stage breast cancer patients, the extent to which these results reflect broader cancer experiences and current practice is unclear. In addition to barriers, the impact of uptake also needs to be considered to guide ethical models of care. Evidence regarding the psychologically impact of tumour profiling is mixed: while some patients report benefits such as empowerment, closure and meaning even when results are not clinically actionable [9], other studies have found that receiving non-actionable results, or actional results without ensured access to treatment can increase distress and disappointment [10]. Health professional have also raised concerns about negative impacts, such as financial burden to patients [11]. An Australian survey of oncologists suggests that most medical oncologists have cared for patients who have self-funded direct-to-consumer tumour testing [12]. Self-funding of testing increases risk of financial burden, can widen inequalities and may restrict shared decision-making opportunities if patients are seeking testing independently of care teams. A greater understanding of how patients feel impacted on balance (weighing the positive and negative impacts) would be useful for guiding ethical decision-making in practice. Caregiver experience should also be explored [6, 13]. Caregivers for cancer patients are at a high risk of both anxiety and depression, and experience caregiver burden [14, 15]. The extent to which caregivers experience benefits or harm from tumour profiling practices, especially for those whose loved ones have not survived cancer, is unknown. Finally, consumer involvement in developing models of tumour genetic profiling that could address access barriers and streamline services is needed. Central models of care, molecular tumour boards, education for patients, increased access to clinical trials, and robust consent processes have been proposed as ways to improve consumer experiences [12, 16–18]. However, we don’t yet know how consumers feel about such options, and how to best allocate resources to provide equitable access to the services that consumers value. Whilst research on consumer perspectives and experiences with cancer genomic testing is building [5, 19, 20], there remain significant gaps in our understanding. There has also been a notable lack of consumer involvement in the research process. Involving consumers (patients and caregivers) in research is considered best practice in Australia and many other western countries [13], as it helps ensure that research outputs align with the interests of the target population and fosters trust in the healthcare system [21]. The current study is consumer-led, with the research aims, study design, and interpretation of results led by patients and caregivers with a lived experience of tumour genomic profiling. The aims were developed in the context of a wider initiative, aiming to develop a roadmap for equitable tumour profiling within Victoria, Australia [16]. The specific aims of the study were to (1) explore knowledge and awareness of tumour genetic profiling among consumers, (2) gain a multi-faceted understanding of consumer experiences of tumour genetic profiling, and (3) explore consumer priorities for improving access and delivery of tumour profiling within Victoria, Australia. It is hoped that the knowledge gained will assist health professionals and policy makers to develop patient-centred approaches to genomic profiling, and in turn, increase uptake and improve outcomes for cancer patients, families, friends, and carers. Methods Study design A consumer-led cross-sectional study involving the completion of an online survey from January to May 2024 was conducted. Ethics approval was obtained from the University of Melbourne Human Ethics Committee (#27758). The study is reported in line with the GRIPP2 checklist for projects involving patient and public involvement in research [22]. Consumer-led research process A consumer reference group (CRG) was established by the Victorian Comprehensive Cancer Centre (VCCC) Alliance as part of the Personalised Cancer Care Program under the Strategic Program Plan 2020–2024. Eight consumers with a history of cancer and knowledge of personalised cancer care and tumour genomic profiling were recruited by the VCCC Alliance through an expression of interest process across metropolitan and regional Victoria. The opportunity was promoted via the VCCC alliance electronic newsletters, social media channels and cancer advocacy networks. Recruitment occurred via a two-step process including a written application and follow-up introductory meeting to explore consumer’s experiences of personalised cancer care and tumour genomic profiling. The purpose of the CRG was to utilise the expertise of lived experiences to support planned research activities. Consumers were upskilled in research through a series of educational workshops (see Supplementary File 2) aligned to key milestones within the project and were supported by the research team to develop the research questions. Early in the project, the CRG (with support from VCCC Alliance staff), developed the Project Responsibility Assignment Matrix to clarify specific roles and responsibilities (i.e. Responsible; Accountable; Consulted; and Informed) throughout the project's lifecycle. The matrix (see Supplementary File 2) was reviewed by the CRG throughout each project stage as deliverables and activities emerged. Researchers from the University of Melbourne were contracted to support the CRG to develop research questions and conduct a study. To provide the CRG with an evidence-informed foundation and ensure that consumers could build upon what was already known, the supporting researchers conducted a rapid review of the literature [23]. Findings from the review, presented as “what is currently known” and “what is unknown” were presented to the CRG via a brief video. Key studies most in line with interests expressed by the CRG were also presented in the video to provide insight into possible research approaches [24, 25]. At the end of the video, the CRG were asked to reflect on their ideas and were sent a survey link that asked them to write down a research aim (“consider what you want to know and why”) and a question they could ask relating to this aim. The research team then facilitated a two-hour workshop with the CRG drawing on co-design methodology [26] to help consumers further explore which research questions were most important to them based on insights from the pre-workshop survey [27]. Tools like PICO [28] and FINER [29] were utilised to help consumers think through the “ingredients” of a research question, and how to ensure the research was feasible and impactful. The research questions were broadly agreed upon by the end of the workshop. The research team then drafted the study protocol, which was reviewed and refined by the CRG in further workshops and via email. The research team held responsibility for conducting the study and preparing the manuscript under the direction of the CRG. To ensure all phases of the study remained consumer-led, online meetings were conducted regularly (including during protocol development, recruitment, data analysis and manuscript preparation), with all CRG members actively contributing and the balance of decision-making resting with the consumers. Additional information as per the GRIPP2 checklist is available in supplementary file 3. Participants and procedure Survey participants were recruited via a variety of channels. CRG members and VCCC Alliance staff reached out to their networks, including cancer specific charities and support organisations who disseminated the survey link via newsletters, email, and social media posts. The research team supported recruitment by disseminating study information to cancer specific research registries (e.g., Breast Cancer Network Australia), professional networks, prior research participants, and via paid social media posts on Facebook. Participants were eligible to participate if they were aged ≥ 18 years, had been diagnosed with cancer or had been a carer for someone who had been diagnosed with cancer, the team managing the cancer treatment was located in Victoria, Australia, and they were able to complete the survey in English or had someone who was able to help them complete the survey in English. Participants were excluded if cancer treatment and management occurred entirely outside the state of Victoria or if they resided outside of Australia. The survey was conducted using REDCap electronic data capture tools hosted at The University of Melbourne [30, 31]. All potentially eligible participants were directed to the online survey where they could read the study information sheet and complete a screening questionnaire. If the screening questionnaire identified someone as being both a patient and carer, they were directed to complete patient focused questions only. Eligible participants provided consent and completed the survey online. Upon survey completion, participants could leave contact details if they wished to enter the draw to win one of five AUD$50 GiftPay vouchers. These vouchers could be used at major supermarkets, retail stores, or donated to charity. Survey The survey was drafted by academic leads (CES, SS) based on detailed conversations and direction from the CRG. The final survey collected detailed background information (demographics and health characteristics), as well as questions relating to each aim. Patients were asked to reflect on their own experiences, whereas carers were asked to provide details relating to the person they cared for, as well as answer questions from their own perceptive (i.e., priorities for improving testing). To increase the likelihood that participants would be able to accurately self-report testing and answer related questions in a valid way, a detailed description of genomic tumour profiling was collaboratively drafted with the CRG and included at the beginning of the survey. Where available, existing measures were utilised or adapted. Otherwise, measures were purpose-build for this study. The survey captured qualitative input via free-text ‘Other, please specify’ responses attached to multiple-choice items and an optional open-ended comments box at the end. These text entries provided brief elaborations to be used alongside quantitative results. The full survey is available to view in Supplementary File 4. A brief overview of measures is provided below. Knowledge and awareness of tumour genetic profiling (Aim 1) Three items were used to assess concepts relating to knowledge and awareness of tumour genetic profiling, including if discussions about tumour genetic profiling had occurred with the treatment team (purpose-built item), level of familiarity with the concept [32], and sources of information (if any) [32]. The item and response options are presented in Table 2 with summary statistics. Table 2Awareness of tumour genetic profilingPatientCarerTotal N=157N = 38N = 195Did anyone in the treatment team discuss tumour genetic profiling with you as part of your treatment planning (as part of treatment planning for the person care/cared for)? Yes36 (23)8 (21)44 (23) No86 (55)21 (55)107 (55) Not that I remember35 (22)9 (24)44 (23)Prior to commencing this survey, how familiar were you with the concept of tumour genetic profiling? Not at all43 (27)10 (26)53 (27) A little63 (40)10 (26)73 (37) Somewhat28 (18)12 (32)40 (21) Very15 (10)2 (5)17 (9) Extremely8 (5)4 (11)12 (6)From where have you learned most about tumour genetic profiling?* Health care professional29 (25)8 (29)37 (26) Participating in research studies9 (8)1 (4)10 (7) Reading research papers17 (15)2 (7)19 (13) Searches on the internet21 (18)8 (29)29 (20) Advertising on the internet1 (1)1 (4)2 (1) Social media5 (4)1 (4)6 (4) Films, TV, other media (e.g., newspaper articles)9 (8)4 (14)13 (9) Friends or family12 (11)1 (4)13 (9) Other11 (10)2 (7)13 (9)*Excluding respondents who responded, ‘Not at all’ to “Prior to commencing this survey, how familiar were you with the concept of tumour genetic profiling?” (Patients, N=43; Carers, N=10) Awareness of tumour genetic profiling *Excluding respondents who responded, ‘Not at all’ to “Prior to commencing this survey, how familiar were you with the concept of tumour genetic profiling?” (Patients, N=43; Carers, N=10) Consumer experiences of tumour genetic profiling (Aim 2) To assess uptake of testing, participants were asked if they (or the person they care/cared for) ever had a test for tumour genetic profiling. This item was purpose built for this study and included “yes”, “no” or “unsure” as response options. Participants that responded “yes” were directed to questions focused on the details of the test (e.g., cost, see Table 3), how information was presented [33], their level of understanding [33] (see Table 4), shared decision-making [34, 35], and decision regret [36, 37]. The shared decision-making scale included 4 items (e.g., “How much did you and your health care providers talk about the reason you (the person you care/cared for) might/might not want to have tumour genetic profiling?”) and was scored according to the partial credit scoring instructions outlined in Valentine et al. [34]. The scale range is 0–4, with a higher score equating to higher shared decision-making. The decision regret scale included 5 items (e.g., “I regret the choice that was made”) ranging from 1–5 (strongly disagree-strongly agree), scored according to [36] on a scale of 0–100 with a higher score indicating higher regret. Participants who answer “yes” to tumour profiling were also directed to questions focused on the usefulness of results, what they gained, any drawback of test results (see Table 5), as well as rating the overall impact of testing (“Overall, how would you rate the impact of tumour genetic profiling on you personally/on the person you care/cared for?”) on a Visual Analogue Scale (0–100). Participants that responded “no” were directed to a question as to the reason why they did not undergo testing (see Table 7). Table 3Circumstances first (and often only) genetic testing undertaken in 1 st Experience(n = 41)*2nd Experience(n = 6)□3rdExperience(n = 2)+Year of testing Last five years29 (70%)42How was testing arranged? Through the treatment team/medical specialist28 (68%)31 Through a research project or clinical trial6 (15%)2 Arranged on own through a private service3 (7%)11 Other4 (10%)Cost of testing $026 (63%)41 $100–10008 (20%)21 $3000-$70007 (17%)0Amount of travel needed (KM) 0–100 km35 (88%)52 100 + km5 (12%)1Type of cancer test conducted for Breast13 (32%)1 Prostate1 (2%)11 Lung7 (17%)1 Colorectal3 (7%) Leukemia3 (7%)11 Ovarian2 (5%) Sarcoma2 (5%)1 Head and neck2 (5%) Other8 (20%)1Cancer stage at time of testing Stage 16 (15) Stage 26 (15)21 Stage 310 (25) Stage 413 (33)3 Unsure5 (13)11Timing of test At diagnosis or soon after26 (65)21 During initial treatment review4 (10)1 During watchful waiting7 (18)11 With progression3 (8)2□Data provided from n = 3 patients and n = 3 carers. Percentages omitted due to low sample numbers+Data provided from n = 2 patients. Percentages omitted due to low sample numbers*Data provided from n = 33 patients and n = 8 carers, includes n = 6 who reported multiple instances Circumstances first (and often only) genetic testing undertaken in □Data provided from n = 3 patients and n = 3 carers. Percentages omitted due to low sample numbers +Data provided from n = 2 patients. Percentages omitted due to low sample numbers *Data provided from n = 33 patients and n = 8 carers, includes n = 6 who reported multiple instances Table 4Communication and understanding of resultsPatientCarerTotalN = 35N = 9N = 44How did your physician present the tumour genetic profiling test results?□ Numbers (i.e., 6% chance)14 (40)2 (22)16 (36) Words (i.e., ‘low risk’ or ‘high risk’)19 (54)7 (77)21 (48) Graphics (i.e., charts)9 (26)1 (11)10 (23) No feedback/waiting for results5 (14)05(11)How much did you understand what you were told about your treatment choices based on the tumour genetic profiling test? Nothing at all3 (9)3 (33)6 (14) Some things10 (29)2 (22)12 (27) Most things14 (40)3 (33)17 (39) Everything5 (14)0 (0)5 (11) Missing3 (9)1 (11)4 (9)□Multiple responses could be recorded Communication and understanding of results □Multiple responses could be recorded Table 5Participant quotes detailing issues experienced with communication of resultsCommunication issuesResults not communicatedNever heard back from CaSP as to results of testing. ID 35, patient, 75 years, 36 years post-diagnosis, melanoma and head and neck cancerLack of communication between care teamIt takes months to get results, which is fine, but they are absolutely terrible at communicating the results with my oncologist. I'd really love to be sent a copy of their results so I can attempt to understand them better, and if they could send them to my GP and oncologist too so I'm not trying to convey messages I don't really understand. Chemo destroyed my memory and I need all the medical people to keep all the other medical people in the loop. ID 88, patient, 40 years, 2 years post-diagnosis, colorectal cancerDidn’t get support/help to understand results in detailI think it would be useful to be able to access someone with specialised knowledge in the area to discuss the results with, in order to better understand them. our Oncologist is wonderful, but time constraints meant that I didn't get the time to discuss and understand these in detail. ID 268, carer, 45 years, 0 years post-diagnosis, neuroblastomaClinician unable to interpret resultsClinician not able to interpret results. I did that myself. ID 210, patient, 49 years, 2 years post-diagnosis, lung cancerDidn’t get support to understand results, results took a long timeGenetic profiling took nearly 5 months and then after the Oncologist told us in 2 sentences what it was (basically told us nothing.) We were then forced to go on Social media to learn more. We didn't get to see Genetic Counselor till 3 weeks later. ID 316, carer, 59 years, 6 years post-diagnosis, breast and kidney cancerPatients: N=121 reported one cancer type, N=24 reported two ormore cancer typesCarer: N=25 reported one cancer type, N=10 reported two or morecancer types.□Respondents could list more than one cancer type*Carers completed these questions in relation to the person they cared forBolded text refers to participant characteristics that made the quote Participant quotes detailing issues experienced with communication of results Patients: N=121 reported one cancer type, N=24 reported two ormore cancer types Carer: N=25 reported one cancer type, N=10 reported two or morecancer types. □Respondents could list more than one cancer type *Carers completed these questions in relation to the person they cared for Bolded text refers to participant characteristics that made the quote Table 7Quotes illustrating benefits and drawbacks of tumour genetic profilingPositive ImpactsKnowledgeEmpowermentFor me, I liked having as much knowledge about what was happening to me as possible. It helped me to cope and made me feel empowered to make the best decisions for me going forward. It also helped me to talk about what had happened to my family and colleagues. ID 29, patient, 37 years, 4 years post-diagnosis, colorectal cancerKnowledge and treatment decision- makingGenetic profiling provided me with crucial information regarding my tumour type and treatment type required. It helped reduce anxiety knowing I had some key information to assist me with decision-making for ongoing treatment and my pathway ahead. ID 231, patient, 52 years, 4 years post-diagnosis, breast cancerPersonalised treatment options, treatment decision-makingFor me the genetic testing was part of my Allogenic Stem Cell Transplant procedure and since then when I have had an issue my Haematologist has been able to discount certain conditions as we have access to this valuable information. ID 78, patient, 66 years, 10 years post-diagnosis, leukemiaPersonalised treatment options, No equity of accessOncotype Dx test was not subsidized by Medicare so my oncologist could not mention it, as many people can't afford it and then would be very distressed…luckily i found out about it on my own through internet and Pubmed research and asked my oncologist about having it—to his and my huge relief hospital pathology could easily organize it. The results were essential in deciding my future treatment. ID 80, patient, 60 years, 10 years post-diagnosis, breast cancerPersonalised treatment options. No equity of accessMy oncologist phoned me on a Friday evening to advise the results (amazing commitment) which supported my decision to not have chemotherapy…I was grateful to have the financial capacity to access this and realise many wouldn't. ID 82, patient, 66 years, 4 years post-diagnosis, breast cancerPersonalised treatment options, reduced unnecessary treatmentPrior to test I was receiving a generic treatment. Post test I was able to receive a targeted treatment. Saved a lot of radio and chemo. ID 355, patient, 50 years, 1-year post-diagnosis, breast cancer and colorectal cancerPersonalised treatment options, reduced unnecessary treatmentBiopsy was taken by the surgeon at time of diagnosis. No consent for genetic profiling was requested. I have no problem with this as the surgeon was able to fast track access to targeted treatment. ID 202, carer, 51 years, 1-year post-diagnosis, lung cancerSurvival benefitWithout it and the service provided by the [name removed] Institute in connecting me to a trial I would be dead by now instead of enjoying every day. I am so thankful this exists! ID 352, patient, 59 years, 2 years post-diagnosis, pancreatic cancerNegative ImpactsLack of communication, dismissiveI changed oncologist because my first one was extremely dismissive. My second oncologist was the one who organised genetic testing and she was quite frustrated that the previous oncologist hadn't done it. It takes months to get results, which is fine, but they are absolutely terrible at communicating the results with my oncologist. ID 88, patient, 40 years, 2 years post-diagnosis, colorectal cancerNo equity of accessI wish I had been given the option, but I found in the public system these things are not discussed because there is an out-of-pocket cost. Then I would have found out if there were other treatments that may have been beneficial. I also think that in an age of increasingly personalised medicine, that there should be equity of access through government subsidy—otherwise you have one group of people who can have access to this information because they can afford it. ID 46, patient, 50 years, 5 years post-diagnosis, breast cancerCan’t always helpIn the end the cancer is there, and genomics won't always help. Quite often knowing the genomics can't stop the cancer spreading, but you need to know what the facts are. Sometimes Genomics are just the awful facts. ID 175, carer, 63 years, 40 years post-diagnosis, breast and lung cancer and lymphomaDelay in results meant more treatment receivedIf the results had been quicker it would have changed the way the cancer team treated and would have meant less operations and less stress. This was the second breast cancer and the slow result (5 months) also caused issues and long delays to treat the 3rd cancer from the Gene (Kidney cancer). ID 316, carer, 59 years, 6 years post-diagnosis, breast and kidney cancerDisappointment, can’t always helpDisappointment – no new treatment options available. ID 199, patient, 51 years, 12 years post diagnosis, thyroid cancerCan’t always helpDrug development and effective treatments to target tumour mutation not progressed enough—mutation identified considered ultra-rare oncogene. ID 62, patient, 40 years, 14 years post diagnosis, SarcomaFearFear of initial biopsy. ID322, carer, 66 years, not reported, Quotes illustrating benefits and drawbacks of tumour genetic profiling Knowledge Empowerment Improving access and delivery of tumour genetic profiling in Victoria (Aim 3) All respondents were asked to rate the importance (‘Not at all’ to ‘Extremely’ important) of strategies to improving tumour genetic profiling for cancer patients in Victoria (Tables 8 and 9), as well as selecting the MOST important strategy. All participants were also asked who they would prefer to receive test results from and from where they would trust to receive information about tumour genetic profiling (Table 10). Table 8Reasons for not undergoing tumour genetic profilingReasonPatientN = 85CarerN = 21TotalN = 106 N (%) N (%) N (%) Not aware of it73 (86)15 (71)88 (83)Do not understand it5 (6)0 (0)5 (5)Did not feel it would benefit4 (5)0 (0)4 (4)Treatment team did not feel it would have benefit13 (15)6 (29)19 (18)Felt it would cause worry or stress0 (0)0 (0)0 (0)Could not afford it3 (4)1 (5)4 (4)Privacy concerns1 (1)0 (0)1 (1)COVID-190 (0)1 (5)1 (1)Could not access it through Medicare3 (4)1 (5)4 (4)No clinical trials available5 (6)7 (33)12 (11)Would have to travel too far0 (0)0 (0)0 (0)Views of friends and family0 (0)0 (0)0 (0)Religious reasons0 (0)0 (0)0 (0)Other (e.g., diagnosed too long ago, unavailable, discouraged)6 (7)0 (0)6 (6) Reasons for not undergoing tumour genetic profiling Table 9Importance of strategies to improve tumour genetic profilingPatientN = 145CarerN = 36Had testingN = 44Did not have testing*N = 106TotalN = 181N (%)N (%)N (%)N (%)N (%)Tests subsidised by the government Somewhat important19 (13)3 (8)1 (2)14 (13)22 (12) Extremely important122 (84)31 (86)36 (82)84 (79)153 (85)Access to health professionals with improved knowledge of genetic testing Somewhat important21 (15)2 (6)3 (7)17 (16)23 (13) Extremely important117 (81)33 (92)32 (73)81 (76)150 (83)Education to understand genetic testing, including differences between tumour genetic profiling and germline testing Somewhat important30 (21)5 (14)7 (16)22 (21)35 (19) Extremely important109 (75)30 (83)29 (66)76 (72)139 (77)Access to genetic counsellors Somewhat important33 (23)7 (19)8 (18)26 (25)40 (22) Extremely important93 (64)26 (72)26 (59)62 (58)119 (66)Access to research studies Somewhat important44 (30)11 (31)9 (20)34 (32)55 (30) Extremely important87 (60)23 (64)28 (64)56 (53)110 (61)Improving the consent process in research studies Somewhat important40 (28)10 (28)7 (16)32 (30)50 (28) Extremely important49 (34)17 (47)15 (34)33 (31)66 (37)NB. Scale included: Not at all, Somewhat unimportant, Neutral, Somewhat important, Extremely, I don’t know*Does not include participants who responded ‘I don’t know’ Importance of strategies to improve tumour genetic profiling NB. Scale included: Not at all, Somewhat unimportant, Neutral, Somewhat important, Extremely, I don’t know *Does not include participants who responded ‘I don’t know’ Table 10Preferred source of tumour genetic profiling informationPatientCarerTotalN = 157N = 38N = 195From where would you trust to receive information about tumour genetic profiling? Health care professional146 (93)36 (95)182 (93) Participating in research studies96 (61)17 (45)113 (58) Reading research papers87 (55)22 (58)109 (56) Searches on the internet34 (22)11 (29)45 (23) Advertising on the internet1 (0.6)0 (0)1 (0.5) Other forms of advertising2 (1)0 (0)2 (1) Social Media1 (0.6)3 (8)4 (2) Films, TV, other media (e.g., newspaper articles)8 (5)1 (3)9 (5) Friends or family14 (9)2 (5)16 (8) Other6 (4)1 (3)7 (4)□ Multiple responses could be recorded Preferred source of tumour genetic profiling information □ Multiple responses could be recorded Background information, including demographics and health related variables Nine items were used to collect demographic information from the sample, including age, location, gender, relationship status, education, employment, income, nationality, and language spoken at home. Ten items were used to collect information regarding health and disease characteristics, including global health status and overall quality of life (EORTC-QLQ-C30) [38], cancer type and stage, time since diagnosis, treatment stage, germline testing, treatments received, hospital type, and allied health services. Statistical analyses Descriptive statistics were calculated for all survey items (for patients and carers separately, and the total sample), using counts and proportions for categorial data, means and standards deviations for parametric continuous data, and medians and ranges for non-parametric continuous data. Qualitative data from open-ended responses were included to augment quantitative results related to the positive and negative impacts of testing (Aim 2). In regard to Aim 2, a logistic regression was conducted (including both patients and carers) to explore the association between shared decision-making (scale range 0–4) and the extent to which patients/carers understood the test results, dichotomised as “nothing at all/some things” to “most things/everything”. To explore whether demographic characteristics were associated with participants’ knowledge and understanding of tumour genetic profiling, additional regression analyses were conducted. Logistic regression was used to examine associations between demographic variables and a dichotomised measure of understanding. Ordered logistic regression was used to examine associations between demographic variables and self-reported knowledge of tumour genetic profiling measured on a five-point ordinal scale (not at all, a little, somewhat, very, extremely). Predictor variables included education, age, gender, marital status, and income. All quantitative analyses were conducted on a complete case basis using STATA 17. Alpha was set a priori at 0.05 with no correction for multiple analyses given the exploratory nature of the survey. Figure 1 was generated using postcode data and symbol-map tool available on datawrapper.de. https://www.datawrapper.de/maps/symbol-map Heat map showing participant location in Victoria, Australia. Darker colours equal higher participant density Free-text responses were analysed using a qualitative descriptive approach. Two researchers (CES, SS) independently coded text inductively, grouped similar codes into descriptive categories aligned to the study aims, and resolved discrepancies by discussion. Findings were used to illustrate and contextualise the quantitative results rather than as a standalone thematic analysis. Results Participant characteristics A total of 475 people commenced the screening questionnaire. Of those, 214 went on to complete the consent form, 195 commenced the survey, and 181 completed the survey (n = 36 carers, n = 145 patients). Demographic characteristics were similar between patients and carer respondents (see Table 1). Participants were mostly female (77%) with a mean (SD) age of 59 [11] years. Just over half were employed (54%), and most had a university education (68%) and resided in a major city (64%). Breast cancer was the most common cancer type among patients (49%), while carers reported a larger variation in cancer types. The majority of carers (64%) reported that the person they had cared for is now deceased. Table 1Summary of participant characteristicsPatientCarerCombinedN = 145N = 36N = 181Age, years (Mean, SD)61 (11)55 (11)59 (11)GenderN (%)N (%)N (%) Male34 (23)6 (17)40 (22) Female110 (76)29 (81)139 (77) Non-binary1 (1)1 (3)2 (1)Location (Fig. 1) Major City90 (62)25 (69)115 (64) Regional55 (38)11 (31)66 (37)Employment Working77 (53)21 (58)98 (54) Retired43 (30)8 (22)51 (28) Other duties/not working/on leave25 (17)7 (19)32 (18)Income Up to $1000 per week45 (31)14 (39)59 (33) $1000 or more per week69 (48)19 (53)88 (49) Prefer not to say31 (21)3 (8)34 (19)Education High school15 (10)4 (11)19 (11) Certificate or Diploma33 (23)6 (17)39 (22) University degree97 (67)26 (72)123 (68)Nationality Australian135 (93)35 (97)170 (94) Other10 (7)1 (3)11 (6)Language other than English at home No127 (88)29 (81)156 (86) Yes18 (12)7 (19)25 (14)HealthMean (SD)Mean (SD)Mean (SD) Global Health Status (1–7)5.12 (1.38)5.37 (1.3)5.17 (1.36) Overall Quality of life (1–7)5.4 (1.29)5.4 (1.53)5.4(1.33) Distrust in health care providers (4–16)7.99(2.07)8.75 (2.12)8.14 (2.10)Cancer type*□N (%)N (%)N (%) Breast71 (49)5 (14)76 (42) Prostate12 (8)4 (11)16 (9) Lung7 (5)5 (14)12 (7) Melanoma9 (6)4 (11)13 (7) Bowel7 (5)6 (17)13 (7) Head and Neck10 (7)4 (11)14 (8) Pancreatic2 (1)4 (11)6 (3) Thyroid3 (2)1 (3)4 (2) Ovarian3 (2)1 (3)4 (2) Cervical2 (1)0 (0)2 (1) Leukemia4 (3)2 (6)6 (3) Lymphoma9 (6)3 (8)12 (7) Myeloma4 (3)1 (3)5 (3) Sarcoma7 (5)6 (17)13 (7) Unknown Primary2 (1)0 (0)2 (1) Other25 (17)8 (22)33 (18)Cancer stage* Stage I/II68 (47)6 (17)74 (41) Stage III/IV50 (35)15 (42)65 (36) Unknown27 (19)13 (36)40 (22) Missing0 (9)2 (6)2 (1) Time since* diagnosisN = 144N = 34N = 178 Mean (SD)7 (7)12 (13)8 (9) Median (Range)5 (0–36)9 (0–45)5 (0–45)Patient Circumstance*N = 145N = 34 Diagnosis, staging and treatment planning3(2)0 Undergoing curative treatment21 (15)3 (9) Care after initial treatment and recovery85 (59)8 (23) Managing recurrent, residual or metastatic disease36 (25)1 (3) End-of-life care01 (3) Deceased021 (62)Patients: N=121 reported one cancer type, N=24 reported two or more cancer typesCarer: N=25 reported one cancer type, N=10 reported two or more cancer types□Respondents could list more than one cancer type*Carers completed these questions in relation to the person they cared for Summary of participant characteristics Patients: N=121 reported one cancer type, N=24 reported two or more cancer types Carer: N=25 reported one cancer type, N=10 reported two or more cancer types □Respondents could list more than one cancer type *Carers completed these questions in relation to the person they cared for The distribution of participants across Victoria (Fig. 1) was reasonably representative of population demography, except for a lack of participants from the northwest of the state [39]. Aim 1: knowledge and awareness of tumour genetic profiling Among both patients and carers, over half the sample (n = 107, 55%) reported that tumour genetic profiling was not discussed with them by a member of the treatment team as part of cancer treatment planning. The majority of patients (N = 106, 68%) and carers (N = 20, 53%) also reported that they were “not at all” or only “a little” familiar with the concept of tumour genetic profiling prior to commencing the survey (Table 2). Among participants who were “a little” to “extremely familiar” (N = 142), they had learned the most about tumour genetic profiling from health care professionals (N = 37, 26%) and internet searches (N = 29, 20%). Additional analyses examined whether demographic characteristics were associated with participants’ knowledge of tumour genetic profiling. Ordered logistic regression showed that education was a significant predictor of familiarity with the concept of genetic profiling. Participants with a university education had greater odds of reporting higher knowledge levels compared with those with a high school education (OR = 2.18, 95% CI 1.22–3.88, p = 0.008). No significant associations were observed for age, gender, marital status, or income. Aim 2: multifaced understanding of consumer experiences of tumour genetic profiling Uptake of profiling A total of 44 (23%) participants reported that they (N = 35, 22%) or the person they care/cared for (N = 9, 24%) had undergone a test for tumour genetic profiling. Of these 44 participants, 41 provided detailed information regarding their testing experiences. The majority (N = 35, 85%) reported only one instance of testing, and 6 reported multiple instances. For the first (and often only) test, the majority of participants reported they had testing in the last five years (n = 29, 70%), accessed testing through their treatment team (n = 28, 68%), accessed testing at diagnosis or soon after (n = 26, 65%), and accessed testing at no cost (n = 26, 63%), and within 100 km from home (n = 35, 88%). Participants who had accessed testing reported a wide range of cancer diagnoses and stages, including those reporting multiple instances of testing. See Table 3 for a detailed description of testing circumstances. Understanding of results and shared decision-making Among those who reported testing, the methods used to communicate testing results were varied (see Table 4). This is further reflected in participant comments. For example, responses ranged from “a full printed report”, and “my oncologist phoned me on a Friday evening to advise the results (amazing commitment)” through to not being provided with results or not receiving adequate support to interpret results. Participant quotes relating to communication issues are presented in Table 5. Understanding of results was also mixed. While 50% of participants reported understanding “most things” or “everything”, 14% reporting understanding “nothing at all”. Out of the nine carers that responded, none reported that they understood “everything” (see Table 4). Additional analyses examined whether demographic characteristics were associated with participants’ understanding of tumour genetic profiling results. Logistic regression analysis indicated that education level was significantly associated with reported understanding. Participants with a university education had greater odds of reporting that they understood “most things” or “everything” compared with those with a high school education (OR = 7.00, 95% CI 1.22–40.09, p = 0.029). No significant associations were observed for age, gender, marital status, or income. Shared decision-making scores ranged from 0–4 (full range of scale), with an average score of 2.10 (SD = 1.23). Health care teams discussing reasons for not having testing and asking if the patient wants to have testing were the poorest scoring items in the scale (see supplementary 5 for individual responses to each item). Using logistic regression analysis (N = 38), a significant association (p = 0.04) was observed between shared decision-making and the extent to which patients/carers understood test results, with the odds of understanding “most things/everything” 1.82 times higher (95% CI = 1.01; 3.28) for each one-unit increase in shared decision-making. Impacts of tumour profiling Impacts of accessing tumour genetic testing were explored in the survey in several ways. Of the 44 participants who reported having a test, 30 patients and 8 carers (N = 38) went on to report a self-rating of overall impact, from 0 (extremely negative) to 100 (extremely positive) (Fig. 2). The overall impact reported based on this item was highly positive (mean, SD = 91, 14; median = 98). A few participants reported more moderate scores (i.e., < 80; N = 4), though the minimum score reported was 50 (neutral). Decision regret was also very low, with participants (n = 38) reporting an average score of 3 (out of 100) where a higher score indicates a higher level of regret (2.7 and 3.4 for patients and carers, respectively). Self-rated impact of tumour genetic profiling The majority of the 44 respondents also rated the test results as extremely useful (n = 27, 61%) or useful (n = 5, 11%). The main positive impacts included increased knowledge and understanding (n = 30, 68%), and more personalised treatment options (n = 23, 52%). Relief about the future (n = 15, 34%), and information relevant to life planning (n = 11, 25%) were also reported (Table 6). Open-ended responses also reflected knowledge and personalised treatment options as being positive impacts (Table 7). One participant felt they had a survival benefit as a result, saying “without it…I’d be dead now”. Others discussed reduced anxiety, feelings of empowerment, and gratitude for avoiding unnecessary treatment. Gratitude was also expressed among those who were in a position to self-fund tests (e.g., “I was grateful to have the financial capacity to access this and realise many wouldn't).” Table 6Benefits and drawbacks of tumour genetic profilingPatientCarerTotalN = 35N = 9N = 44How useful were the test results to you (to the person you care/cared for)? Not at all useful1 (3)1 (11)2 (2) Somewhat useful3 (9)1 (11)4 (9) Useful4 (11)1 (11)5 (11) Extremely useful22 (63)5 (56)27 (61) Missing5 (14)1 (11)6 (14)What do you feel you have gained from your test results (What do you think was gained from the test results)? □ Increased knowledge and understanding23 (66)7 (78)30 (68) Relief from uncertainty about the future13 (37)2 (22)15 (34) More personalised treatment option19 (54)4 (44)23 (52) Information relevant to life planning9 (26)2 (22)11 (25) Other3 (9)1 (11)4 (9) Not applicable – test results are not useful1 (3)1 (11)2 (5)What do you feel were the drawback from your test and/or test results (from the test and/or test results)?□ Financial burden8 (23)1 (11)9 (20) Increased uncertainty3 (9)1 (11)4 (9) Psychological distress2 (6)2 (22)4 (9) Confusion2 (6)3 (33)5 (11) Other2 (6)2 (22)4 (9) Not applicable – no drawbacks experienced16 (46)2 (22)18 (41)□Multiple responses could be recordedBolded text refers to participant characteristics that made the quote Benefits and drawbacks of tumour genetic profiling □Multiple responses could be recorded Bolded text refers to participant characteristics that made the quote When asked about drawbacks of testing (see Table 6), 40% reported no drawbacks at all. Among the remaining participants, financial burden (20%), confusion (11%) and distress (9%) were reported. Further drawbacks were extrapolated from the open-ended questions, where participants commented that they experienced medical teams being dismissive, delays to treatments due to delays in results and results that aren’t necessarily helpful or are disappointing. One carer also noted they felt fear about the initial biopsy. Reasons for not having testing The main reason reported for not having undergone testing was a lack of awareness (n = 88, 83%) (Table 8). This was also reflected in participant comments: “Tumour genetic profiling was not discussed with me, so I wasn't aware it was potentially available to me” (ID 41, patient, 67 years, 3 years post-diagnosis, breast cancer) and “It was not raised as an option by my treatment team. I would have been interested in having it if I knew at the time” (ID 46, patient, 50 years, 5 years post-diagnosis, breast cancer). Among all survey respondents, the top priorities for improving tumour genetic profiling in Victoria were government subsidised tests, access to health professionals, and education resources that could help them understand what testing is, and the results once obtained (Tables 9). When asked to select the most important strategy for improving tumour genetic profiling in Victoria, the majority of participants indicated government subsidised tests (n = 71, 39%), followed by access to health professionals (n = 53, 29%), education resources (n = 48, 27%), and access to genetic counsellors (n = 9, 5%). The second most common reason was the treatment team not seeing the benefit (n = 19, 18%). Some participants reported feelings of being “discouraged” to have testing and “pressured” to have treatment. Participants commented: “The benefits were not explained to me and I was discouraged from having a test even though the multi-disciplinary team recommended it as an option for me”( ID 164, patient, 63 years, 2 years post-diagnosis, breast cancer); “Treatment team pressured me to go ahead with treatment without the test and would not explain what genomic testing would tell me” (ID 419, patient, 63 years, 2 years post-diagnosis, breast cancer) and “The treatment team did not bring it up, we did. They offered to do it but said it would be time consuming and expensive” (ID 240, carer, 51 years, 0 years post-diagnosis, endometrial cancer). Access issues were also identified, with 11% (n = 12) reporting there were no clinical trials available and 4% (n = 4) reporting they could not afford testing. No participants reported avoiding testing due to worry or stress, views of friends/family, or religious reasons. Aim 3: improving access and delivery of tumour genetic profiling in Victoria Treatment teams were preferred by the majority of people (N = 118, 65%) for providing information on results, compared to a centralised service with expertise in tumour profiling (n = 63, 35%). Though it was noted in participant comments that a centralised service to ask questions, given treatment team availability, would be appreciated: “Whilst I would like to access my results from my treating team I would also prefer a centralized service to be able to ask for questions and more information about the results if needed due to the limitations of a clinicians time and in some cases knowledge” (ID 44, patient, 41 years, 9 years post-diagnosis, lung cancer). Over half of participants also reported that they would trust information about tumour genetic profiling from healthcare professionals (n = 182, 93%), research studies (n = 113, 58%), and research papers (n = 109, 56%) (Table 10). Discussion This study aimed to inform the development of patient-centred approaches to genetic profiling by providing insights into current awareness levels about tumour genetic profiling, lived experiences of accessing and utilising tumour genetic profiling (or not), and priorities for improving access and delivery of tumour profiling among cancer patients and carers in Victoria, Australia. The findings highlighted significant gaps in consumer knowledge and access, the benefits of shared decision-making, and key strategies for improving equitable access to tumour genetic profiling services. These results have important implications for healthcare providers, policy makers, and researchers aiming to enhance the delivery of personalised cancer care. The points considered most important by the CRG were recorded (see supplementary file 6) and are discussed below. Awareness and access to tumour genetic profiling A major barrier identified was the lack of awareness among consumers regarding tumour genetic profiling. More than half of respondents (55%) reported that tumour genetic profiling was not discussed with them by their treatment team, and 83% of those who had not undergone testing cited lack of awareness as a key reason. These findings align with previous research indicating that many patients remain uninformed about genetic testing options and their potential benefits [7]. In our study, higher education was associated with greater familiarity with tumour genetic profiling, suggesting that awareness of testing may be unevenly distributed across educational groups. In an Australian context, publicly funded testing is more available to patients with advanced cancer and poor prognostic features. This context may partially explain the low levels of awareness we observed, as many of our participants had early-stage disease. Further, prior research suggests that clinicians may be hesitant to raise testing if they perceive its clinical utility or availability to be low [40]. This is problematic from the perspective of patient-centred care, as patients and carers may have different views about clinical utility than their care team. A recent survey of 602 Australians undergoing cancer genetic sequencing (probands) and their relatives showed that more than half of the sample population thought people would still want to know about single gene conditions that have no prevention or treatment options [41]. Further, in our study, there were psychological benefits of testing, with some participants reporting that having testing made them feel empowered and helped them to cope. Overall, there seems to be a clear need for education across the board on the use and benefits of testing. Clinicians will also likely need increased support interpreting results and testing will need to become more widely available before they commence conversations about tumour genetic profiling as common practice [42]. Although improving in Australia, access to tumour genetic profiling remains an issue [16]. Disparities in access were evident in the current study. While some patients benefited from tumour genetic profiling at no cost, others faced financial barriers, with some self-funding testing due to limited public funding. Government-subsidised testing was identified as the highest-priority strategy for improving access, with 85% of respondents rating it as extremely important. These findings reinforce the need for policy changes to expand access to evidence-based tumour genetic profiling [43]. Consumer experiences with tumour genetic profiling For those who had undergone tumour genetic profiling, the majority reported positive experiences, particularly in terms of increased knowledge and personalised treatment options. The reported decisional regret was extremely low, further supporting the value of tumour genetic profiling in cancer care. However, there were notable challenges related to understanding results, with 14% of respondents reporting no understanding of their test results at all, which may be particularly the case for individuals with lower levels of education. The study identified an association between shared decision-making and better understanding of test results. This finding underscores the importance of clinician engagement and patient and caregiver involvement in the decision-making process. Although decision regret was low, clinicians should be aware that for some consumers, genomic testing presented them with just the “awful facts”. Clear and supportive communication from healthcare providers, including access to genetic counsellors and structured educational resources, could enhance patient and caregiver comprehension and overall experience with tumour genetic profiling [44]. Priorities for improving tumour genetic profiling access and delivery In addition to public funding for tumour genetic profiling, participants emphasised the need for increased clinician education and access to health professionals knowledgeable about genetic testing. Many respondents reported that their healthcare providers did not offer tumour genetic profiling or did not discuss its potential benefits. Education initiatives aimed at oncologists and other healthcare professionals could improve clinician confidence in discussing and recommending tumour genetic profiling to patients [45, 46]. As part of this, clinicians should be made aware of the impending ban on the use of adverse testing by life insurers in Australia [47], as multiple qualitative responses implied worries about such when considering undergoing testing. Participants also expressed strong support for a centralised service to provide additional information and support regarding tumour genetic profiling. While 65% of respondents preferred to receive test results from their treatment team, 35% indicated interest in a specialised centralised service for testing related queries. Evidence from “mainstreaming” models, where oncology teams provide pre-test counselling, order testing, and return results, with genetics services engages for positives/complexes cases, shows high update, satisfaction and lower post-test decision conflict compared to genetics-led pathways [48]. Taken together, these data support a hybrid model, combining direct clinician involvement with accessible, specialised support services to enhance patient understanding and decision-making. Implications for healthcare professionals and policy makers These findings highlight the critical role of healthcare professionals in facilitating patient access to and understanding of tumour genetic profiling. Training programs for oncologists, general practitioners, nursing and allied health professionals should include education on how to effectively communicate the benefits and limitations of tumour genetic profiling, as well as the importance of shared decision-making. Previous research in oncology has shown that training on shared decision-making can lead to behaviour change among clinicians [49]. Providing patients with question prompt lists is also likely to improve patient-centred communication [50]. For policy makers, this study underscores the urgency of expanding public funding for tumour genetic profiling to ensure equitable access. The cost-effectiveness of genetic testing in oncology has been demonstrated in international studies, with evidence suggesting that subsidising tests such as Oncotype DX can reduce the need for costly chemotherapy treatments [51]. Avoiding unnecessary chemotherapy also reduces the financial and health burden associated with managing the short and long-term side-effects of chemotherapy (e.g., fatigue, cardio-toxicity [52]). Incorporating holistic cost–benefit analyses in the Australian healthcare context that take health system and patient costs into account could support policy changes that increase funding for tumour genetic profiling. Additionally, addressing the identified communication gaps by implementing national guidelines for discussing genetic testing in cancer care could standardise practice and improve patient experiences [43]. Such guidelines should not only encourage routine communication about the potential role of tumour genetic profiling but also provide clear recommendations about when testing is and is not medically indicated. This would support shared decision-making by ensuring that patients understand both the potential benefits and the limitations of testing in their particular clinical context. Importantly, it may also help reassure patients that decisions not to undergo testing are evidence-based and appropriate, thereby reducing uncertainty and potential decisional regret. Policymakers should also consider supporting infrastructure for mainstreaming genetic services with specialist support that can provide expert guidance alongside routine oncology care [48, 53]. Limitations and future research While this study provides important insights, several limitations should be considered. The cross-sectional design does not allow for causal inferences, and the sample, though diverse, was skewed toward highly educated individuals and those with breast cancer. Given that breast cancer patients typically have greater access to support due to high funding levels [54], the experiences reported here may not be fully representative of other cancer populations. Future research should aim to capture a broader range of cancer experiences and explore differences in genetic testing access across diverse demographic groups. Another limitation was the reliance on self-reported data, which may be subject to recall bias. Despite providing participants with a detailed description of tumour (somatic) genetic profiling at the beginning of the survey, it is possible that some respondents misinterpreted questions and answered in relation to germline testing. As experiences and expectations can differ between somatic and germline testing, this potential misclassification should be acknowledged. While comparing survey responses with medical records would provide further insight into the accuracy of recall, such validation was beyond the scope of this consumer-led study, which was focused on capturing lived experiences and perspectives. Additionally, the relatively small number of participants who had undergone tumour genetic profiling limited the statistical power for subgroup analyses. Future research conducted across multiple sites, with recruitment occurring at the point of diagnosis and longitudinal follow-up, would help address these issues by increasing sample size, validating testing status, and providing more comprehensive insights into the long-term impact of tumour genetic profiling. Conclusion This consumer-led study highlighted the substantial gaps in awareness and access to tumour genetic profiling, the benefits of shared decision-making, and the priorities for improving equitable service delivery. Findings reinforce the need for increased public funding, enhanced clinician education, and better communication strategies to ensure patients receive timely and comprehensible information about tumour genetic profiling. The study provides actionable insights for healthcare professionals and policy makers seeking to implement person-centred, equitable, and ethical models of genetic testing in oncology. Supplementary Information Supplementary Material 1. Australian genomic profiling landscape. Supplementary Material 2. Consumer Workshops. Supplementary Material 3. GRIPP2 reporting. Supplementary Material 4. Study survey. Supplementary Material 5. Shared decision making scores. Supplementary Material 6. Consumer reflections on findings. Acknowledgements We gratefully acknowledge the valuable contributions of our consumer advisors, whose expertise and generosity extend across many organisations. In addition to their roles on this project, they serve in a range of advisory capacities that highlight the breadth of their impact. We also acknowledge the possibility that these organisations may have provided training or support to our consumer team over time. Kathleen Minas, Naveena Nekkalapudi, and Jonathan Granek are members of the Consumer Advisory Panel and Consumer Program at the Walter and Eliza Hall Institute of Medical Research. Naveena Nekkalapudi also serves as an active consumer representative with Breast Cancer Network Australia (BCNA). Jonathan Granek is the Founding Director and Chair of the EHE Rare Cancer Foundation Australia and holds additional roles as a member of the Community Advisory Committee and Consumer Register at the Peter MacCallum Cancer Centre; Ordinary Member (Consumer) of the Australian and New Zealand Sarcoma Association; Allied Health Professional (Consumer Advocate) with the Connective Tissue Oncology Society; and Consumer Representative and Advocacy Group Partner with Omico (Australian Genomic Cancer Medicine Centre). Melissa Sheldon is Co-chair of the Community Action Team (ComAct) within the Melanoma & Skin Cancer Advocacy Network and serves as a Consumer Advisor on the Consumer Advisory Committee (CAC) at Echuca Regional Health (ERH). Kenneth Young is a volunteer with MPN Alliance Australia. We also sincerely thank all the patients and carers who generously shared their experiences by participating in this study, as well as the organisations, support groups, and networks across Victoria who assisted with recruitment and survey dissemination. Abbreviations Tumour Genetic Profiling Victorian Comprehensive Cancer centre Consumer Reference Group Standard Deviation European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Research Electronic Data Capture General Practitioner Patient/Population, Intervention, Comparison, Outcome Feasible, Interesting, Novel, Ethical, Relevant Guidance for Reporting Involvement of Patients and the Public (Version 2) Identifier (used for anonymised participant quotes). Australian Dollar Authors’ contributions Conceptualization: All authors. Investigation: All authors. Methodology: All authors. Formal analysis: CES, TJ. Project administration: GD, CES, JMB, NC, MB, MB, KM. Writing – original draft: CES, SS. Writing – review & editing: All authors. All authors read and approved the final manuscript. Funding The Personalised Cancer Care Consumer-led Research Project was supported by the Victorian Comprehensive Cancer Centre (VCCC) alliance as part of the Strategic Program Plan 2021–2024 with funding from the Victorian Government. Data availability All de-identifiable data and materials associated with this project can be requested by contacting the corresponding author. Declarations Ethics approval and consent to participate Ethics approval was obtained from the University of Melbourne Human Ethics Committee (#27758). All participants provided written informed consent online via REDCap and have been informed that no identifying details will be published in this manuscript. Our study adhered to the Declaration of Helsinki. Competing interests The authors declare no competing interests. Footnotes Victorian Comprehensive Cancer Centre (VCCC) Alliance Personalised Cancer Care Consumer Reference Group are equal first authors. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Research Support Team (University of Melbourne), Email: camille.short@unimelb.edu.au. Victorian Comprehensive Cancer Centre (VCCC) Alliance Personalised Cancer Care Consumer Reference Group: Kathleen Minas, Melissa Sheldon, Sonja Ilievska, Naveena Nekkalapudi, Kenneth Young, Jonathan Ashley Granek, Victoria Sharp, and Beth Doggett Victorian Comprehensive Cancer Centre (VCCC) Alliance staff: Genevieve Dall, Joanne M Britto, Nonie Chan, Michelle Barrett, and Mark Buzza Research Support Team (University of Melbourne): Tamara Jones, Sarah Stratulate, and Camille E Short References Associated Data Supplementary Materials Supplementary Material 1. Australian genomic profiling landscape. Supplementary Material 2. Consumer Workshops. Supplementary Material 3. GRIPP2 reporting. Supplementary Material 4. Study survey. Supplementary Material 5. Shared decision making scores. Supplementary Material 6. Consumer reflections on findings. Data Availability Statement All de-identifiable data and materials associated with this project can be requested by contacting the corresponding author.